Preischemic Iloprost Application for Improvement of Graft Preservation: Which Route is Superior in Experimental Pig Lung Transplantation: Inhaled or Intravenous?

Transplantation Proceedings

Volumn 39, Issue 5, 2007, Pages 1345-1349

  Wittwer, T ^a   Franke, U F ^a   Sandhaus, T ^a   Thiene, M ^a   Groetzner, J ^a   Strauch, J T ^a   Wippermann, J ^a   Ochs, M ^a   Muehlfeld, C ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ILOPROST; PROSTANOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; EXPERIMENTAL MODEL; FEMALE; GRAFT SURVIVAL; LUNG COMPLIANCE; LUNG HEMODYNAMICS; LUNG TRANSPLANTATION; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; REPERFUSION INJURY; SWINE;

ADMINISTRATION, INHALATION; ANIMALS; GRAFT SURVIVAL; ILOPROST; INJECTIONS, INTRAVENOUS; LUNG TRANSPLANTATION; MODELS, ANIMAL; PLATELET AGGREGATION INHIBITORS; REPERFUSION INJURY; SWINE;

EID: 34250204073     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.03.065     Document Type: Article

References (24)

1. Van Raemdonck D., Strüber M., Venuta F., et al. Strategies in the prevention and the treatment of ischemia-reperfusion injury after lung transplantation. Eur Respir Mon 29 (2004) 66
2. Trulock E.P., Edwards L.B., Taylor D.O., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report-2005. J Heart Lung Transplant 24 (2005) 956
3. Sakamaki F., Hoffmann H., Mueller C., et al. Reduced lipid peroxydation and ischemia-reperfusion injury after lung transplantation using low-potassium dextran solution for lung preservation. Am J Respir Crit Care Med 156 (1997) 1073
4. Wittwer T., Franke U., Fehrenbach A., et al. Experimental lung transplantation-impact of preservation solution and route of delivery. J Heart Lung Transplant 24 (2005) 1081
5. Wittwer T., Franke U., Fehrenbach A., et al. Impact of retrograde graft preservation in perfadex-based experimental lung transplantation. J Surg Res 117 (2004) 239
6. de Perrot M., and Keshavjee S. Lung preservation. Semin Thorac Cardiovasc Surg 16 (2004) 300
7. Gohrbandt B., Sommer S.P., Fischer S., et al. Iloprost to improve surfactant function in porcine pulmonary grafts stored for twenty-four hours in low-potassium dextran solution. J Thorac Cardiovasc Surg 129 (2005) 80
8. Fiser S.M., Cope J.T., Kron I.L., et al. Aerosolized prostacyclin (Epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg 121 (2001) 981
9. Wittwer T., Franke U.F.W., Fehrenbach A., et al. Donor pretreatment using the aerosolized prostacyclin analogue iloprost optimizes postischemic function of non heart beating donor lungs. J Heart Lung Transplant 24 (2005) 371
10. Hopkinson D.N., Bhabra M.S., and Hooper T.L. Pulmonary graft preservation: a worldwide survey of current clinical practice. J Heart Lung Transplant 17 (1998) 525
11. Kimblad P.A., Sjöberg T., Massa G., et al. High potassium contents in organ preservation solutions causes strong pulmonary vasoconstriction. Ann Thorac Surg 52 (1991) 523
12. Fischer S., Matte-Martyn A., dePerrot M., et al. Low-potassium dextran preservation solution improves lung function after human lung transplantation. J Thorac Cardiovasc Surg 120 (2001) 594
13. Baron O., Fabre S., Haloun A., et al. Retrospective clinical comparison of Celsior solution to modified blood Wallwork solution in lung transplantation for cystic fibrosis. Prog Transplant 12 (2002) 176
14. Vane J.R. Adventures and excursions in bioassay-the steping stones to prostacyclin. Postgrad Med J 59 (1983) 743
15. Fantone J.C., Funkel S.L., Ward P.A., et al. Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. J Immunol 125 (1980) 2591
16. Suttorp N., Weber U., Welsch T., et al. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 91 (1993) 1421
17. dePerrot M., Fischer S., Liu M., et al. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti- inflammatoty cytokines. Transplantation 72 (2001) 1505
18. Löckinger A., Schütte H., Walmrath D., et al. Protection against gas exchange abnormalities by pre-aerosolized PGE1, iloprost, and nitroprusside in lung ischemia-reperfusion. Transplantation 71 (2001) 185
19. Olschewski H., Ghofrani H.A., Walmrath D., et al. Inhaled prostycyclin and iloprost in severe pulmonary hytertension secondary to lung fibrosis. Am J Respir Crit Care Med 160 (1999) 600
20. Kawashima M., Nakamura T., Schneider S., et al. Iloprost ameliorates post-ischemic lung reperfusion injury and maintains an appropriate pulmonary ET-1-balance. J Heart Lung Transplant 22 (2003) 794
21. Siobal M. Aerosolized prostacyclins. Respir Care 49 (2004) 640
22. Kukkonen S., Heikkilä, Verkkala K., et al. Prostaglandin E1 or prostacyclin in Euro-Collins solution fails to improve lung preservation. Ann Thorac Surg 60 (1995) 1617
23. Strüber M., Wilhelmi M., Harringer W., et al. Flush perfusion with low potassium dextran solution improves early graft function in clinical lung transplantation. Eur J Cardiothorac Surg 19 (2001) 190
24. Fehrenbach H. Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2 (2001) 33